Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).
|
| Abstract |
ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25-40% and 26-36%, respectively. Fifty-five full completers (54%) reported ≥1 change in adherence category (improvement and/or worsening), most of which were associated with unintentional behavior. The data suggest that one-third of patients receiving ruxolitinib may be undertreated due to non-adherence, potentially undermining disease control, and indicate a need for better interventions addressing noncompliance to oral therapies.
|
|---|---|
| Authors | Paola Guglielmelli, Francesca Palandri, Carmine Selleri, Daniela Cilloni, Francesco Mendicino, Patrizio Mazza, Domenico Pastore, Giuseppe A Palumbo, Marco Santoro, Vincenzo Pavone, Stefana Impera, Mara Morelli, Paola Coco, Diletta Valsecchi, Francesco Passamonti, Massimo Breccia, ROMEI study group |
| Journal | Leukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 1 Pg. 189-198 (01 2022) ISSN: 1029-2403 [Electronic] United States |
| PMID | 34521299 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!